The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Anti-IgE for chronic asthma in adults and children
Abstract
BACKGROUND: Omalizumab is a recombinant humanised monoclonal antibody directed against immunoglobulin E (anti-IgE) to inhibit the immune system's response to allergen exposure. Omalizumab is directed against the binding site of IgE for its high affinity Fc receptor. It prevents free serum IgE from attaching to mast cells and other effector cells and prevents IgE mediated inflammatory changes. OBJECTIVES: To determine the efficacy of anti-IgE compared with placebo in patients with allergic asthma SEARCH STRATEGY: We searched the Cochrane Airways Group Asthma trials register for potentially relevant studies (February 2006). SELECTION CRITERIA: Randomised controlled trials examining anti-IgE administered in any manner for any duration. Trials with co-interventions were included as long as they were the same in each arm. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed study quality and extracted and entered data. Three modes of administration were identified from the published literature (inhaled, intravenous and subcutaneous injection). Subgroup analysis was performed by asthma severity. Data were extracted from published and unpublished sources. MAIN RESULTS: Fourteen trials (15 group comparisons) were included in the review, contributing a total of 3143 mild to severe allergic asthmatic participants with high levels of IgE. Treatment with intravenous and subcutaneous Omalizumab significantly reduced free IgE compared with placebo. Omalizumab led to a significant reduction in inhaled steroid (ICS) consumption compared with placebo (-119 mcg/day (95% CI -154 to -83, three trials)). There were significant increases in the number of participants who were able to reduce ICS by over 50% (odds ratio (OR) 2.50, 95% confidence interval (CI) 2.02 to 3.10 (four trials)); or completely withdraw their daily ICS intake (OR 2.50 (95%CI 2.00 to 3.13; four trials)). Participants treated with Omalizumab were less likely to suffer an asthma exacerbation with treatment as an adjunct to ICS (OR 0.52, 95%CI 0.41 to 0.65, five trials), or as an ICS tapering agent (OR 0.47, 95% CI 0.37 to 0.60, four trials). AUTHORS' CONCLUSIONS: Omalizumab was significantly more effective than placebo at increasing the numbers of patients who were able to reduce or withdraw their inhaled steroids, but the clinical value of the reduction in steroid consumption has be considered in the light of the high cost of Omalizumab. The impressive placebo effects observed in control groups bring into question the true effect of Omalizumab. Omalizumab was effective in reducing asthma exacerbations as an adjunctive therapy to inhaled steroids, and during steroid tapering phases of clinical trials. Omalizumab was generally well tolerated, although there were more injection site reactions with Omalizumab. Patient and physician assessments of the drug were positive. Further assessment in paediatric populations is necessary, as is direct double-dummy comparison with ICS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vignola, A. M., Humbert, M., Bousquet, J., Boulet, L., Hedgecock, S., Blogg, M., Fox, H., & Surrey, K. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00550.x · Cited by 405
Cited by
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Allergen immunotherapy: A practice parameter third update
Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., Nelson, M., Weber, R., Bernstein, D. I., Blessing-Moore, J., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.09.034 · Cited by 1,256
The Journal of Allergy and Clinical Immunology
(1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70212-5 · Cited by 1,093
Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease
Anderson, G. P. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61452-x · Cited by 999
Brożek, J. L., Akl, E. A., Alonso‐Coello, P., Lang, D., Jaeschke, R., Williams, J. W., Phillips, B., Lelgemann, M., Lethaby, A., Bousquet, J., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.01973.x · Cited by 894
“For example, based on a systematic review of monoclonal anti-IgE for chronic asthma in adults and children (58), one might grade the quality of evidence about asthma symptoms, exacerbations, and quality of life as high, but the quality of evidence about adverse effects as moderate.”
MethodOmalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
Gevaert, P., Calus, L., Van Zele, T., Blomme, K., De Ruyck, N., Bauters, W., Hellings, P., Brusselle, G., De Bacquer, D., van Cauwenberge, P., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.047 · Cited by 744
Omalizumab for asthma in adults and children
Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub4 · Cited by 651
Self-citationDiagnosis and treatment of asthma in childhood: a PRACTALL consensus report
Bacharier, L. B., Boner, A., Carlsen, K. ‐., Eigenmann, P. A., Frischer, T., Götz, M., Helms, P. J., Hunt, J., Liu, A., Papadopoulos, N., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01586.x · Cited by 640
Asthma Exacerbations: Pathogenesis, Prevention, and Treatment
Castillo, J. R., Peters, S. P., & Busse, W. W. (2017) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2017.05.001 · Cited by 544
International consensus on (ICON) pediatric asthma
Papadopoulos, N. G., Arakawa, H., Carlsen, K. ‐., Custovic, A., Gern, J., Lemanske, R., Le Souef, P., Mäkelä, M., Roberts, G., Wong, G., et al. (2012) · Allergy · doi:10.1111/j.1398-9995.2012.02865.x · Cited by 455
Acute exacerbations of asthma: epidemiology, biology and the exacerbation‐prone phenotype
Dougherty, R. H., & Fahy, J. V. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.03157.x · Cited by 396
Asthma exacerbations: Origin, effect, and prevention
Jackson, D. J., Sykes, A., Mallia, P., & Johnston, S. L. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.10.024 · Cited by 343
Mosbech, H., Deckelmann, R., de Blay, F., Pastorello, E. A., Trebas-Pietras, E., Andres, L. P., Malcus, I., Ljørring, C., & Canonica, G. W. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.03.019 · Cited by 285
Rodrigo, G. J., Neffen, H., & Castro-Rodriguez, J. A. (2011) · Chest · doi:10.1378/chest.10-1194 · Cited by 268
Severe asthma with fungal sensitization
Agarwal, R. (2011) · Current Allergy and Asthma Reports · doi:10.1007/s11882-011-0217-4 · Cited by 188
“In a metaanalysis of 14 trials (n=3,143 asthmatics), the use of omalizumab was shown to decrease the requirement of ICS and reduce the number of exacerbations [86].”
BackgroundLai, T., Wang, S., Xu, Z., Zhang, C., Zhao, Y., Hu, Y., Cao, C., Ying, S., Chen, Z., Li, W., et al. (2015) · Scientific Reports · doi:10.1038/srep08191 · Cited by 103
Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy
Corren, J., Shapiro, G., Reimann, J., Deniz, Y., Wong, D., Adelman, D., & Togias, A. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.11.026 · Cited by 83
Metadata
- Authors
- Walker, S., Monteil, M., Phelan, K., Lasserson, T. J., & Walters, E. H.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2006-04-19
- Issue
- 2
- Pages
- CD003559-CD003559
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W1828975699
- Cited by
- 236
- References
- 1
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.